Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Community Physician Voices: Exploring Management Options for a College-Age Patient with Vitiligo
Author(s):
Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials.
- What guidance do you provide to patients with vitiligo upon achieving remission with ruxolitinib treatment?
- How do you counsel them regarding ongoing management?
- Do you advise continuing or discontinuing treatment in pigmented versus depigmented areas?
- If faced with this patient, would you have approached treatment in the same manner?
- When it comes to topical ruxolitinib, is it generally covered by insurance, or have you encountered instances where patients had difficulty securing coverage for this treatment?
- How do you navigate such situations?
- Could you share insights on the process of obtaining insurance authorization for vitiligo treatments like topical ruxolitinib?
- What are the typical steps involved, and how do you assist patients in this process?
Related Videos
Related Content
